Fred Hutchinson Cancer Center 
Welcome,         Profile    Billing    Logout  
 13 Products   7 Diseases   13 Products   7 Trials   299 News 


«123»
  • ||||||||||  FH-TCR-T?s?? / Fred Hutchinson Cancer Center
    Trial completion date, Trial primary completion date, Metastases:  Mesothelin-Specific T-Cells (FH-TCR-T?s??) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) -  Apr 20, 2022   
    P1,  N=15, Recruiting, 
    After the first 12 months, patients transition to a long-term follow-up (LTFU) study for up to 15 years as per FDA guidelines. Trial completion date: Nov 2037 --> Apr 2024 | Trial primary completion date: Nov 2022 --> Jun 2023
  • ||||||||||  BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
    Stromal cell derived IL6 inhibits the extrinsic apoptotic pathway in multiple myeloma cell lines (Section 35) -  Mar 9, 2022 - Abstract #AACR2022AACR_4767;    
    Clinical trials have shown that BCMA targeted CAR-T therapy induces MM remission in most patients with heavily pretreated relapsed refractory MM; however, the duration of the response has been disappointing...This suggests that soluble factors in the BMM can convert cells from type I to type II (mitochondrial-dependent) death receptor signaling and that inhibiting BMM signals such as IL6 may enhance FASL-induced cell death in MM. However, the data also demonstrate that the role of FAS in CAR-T killing is cell context dependent.
  • ||||||||||  JCAR 023 / BMS, Fred Hutchinson Cancer Center
    Enrollment closed:  Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 (clinicaltrials.gov) -  Dec 15, 2021   
    P1,  N=65, Active, not recruiting, 
    Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Dec 2024 Recruiting --> Active, not recruiting
  • ||||||||||  TSLPR-directed CAR T / Fred Hutchinson Cancer Research Center
    Immunotherapeutic Targeting of TSLPR with Chimeric Antigen Receptor T Cells in AML (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_4433;    
    We further demonstrate that CAR T cells targeting TSLPR were effective in eliminating AML cells in vitro and in vivo . Given that TSLPR is highly expressed in the KMT2A-rearranged AML, a subtype that is associated with poor outcomes, TSLPR-directed CAR T cells represent a promising immunotherapy for this high-risk AML subset.
  • ||||||||||  CD33PAN CAR T / Fred Hutchinson Cancer Research Center, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
    Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_4420;    
    Targeting the membrane proximal domain of CD33 enhances the anti-leukemic potency of CAR T cells. Our data provide the rationale for the further development of CD33 PAN CAR T cells toward clinical testing.
  • ||||||||||  PRAME mTCR CAR T / Fred Hutchinson Cancer Research Center
    Targeting PRAME with TCR-Mimic CAR T Cells in AML (GWCC - B304-B305, Level 3) -  Nov 5, 2021 - Abstract #ASH2021ASH_2227;    
    We further demonstrate that the activity of PRAME mTCR CAR T cells can be enhanced with IFN-γ treatment, providing a useful strategy to increase efficacy. Thus, the results presented provide a novel approach to target PRAME with CAR T cells and compelling data to evaluate PRAME mTCR CAR T cells in AML clinical trials.
  • ||||||||||  JCAR014 / BMS
    Enrollment closed, Trial primary completion date, Combination therapy:  JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Jun 28, 2021   
    P1b,  N=30, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2034 --> Apr 2021 | Trial primary completion date: Apr 2034 --> Apr 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> May 2021
  • ||||||||||  FCARH143 / BMS, Fred Hutchinson Cancer Research Center, National Cancer Institute
    Enrollment closed, Trial primary completion date, CAR T-Cell Therapy, Metastases:  Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) -  Jun 10, 2021   
    P1,  N=28, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> May 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2022 --> May 2021
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo, JCAR014 / BMS
    [VIRTUAL] CRS AND ICANS RISK ACROSS THREE CD19 CAR-T CELL PRODUCTS IN PATIENTS WITH AGGRESSIVE NHL () -  May 13, 2021 - Abstract #EHA2021EHA_1066;    
    P1/2
    Methods We retrospectively analyzed 136 aggressive NHL pts treated with cyclophosphamide and fludarabine lymphodepletion (LD) followed by CD19 CAR T-cell therapy...We observed higher ICANS severity in older patients treated with axicel; in contrast, age had limited impact on ICANS severity in those receiving tisacel or JCAR014. While further analyses comparing efficacy are warranted, our findings provide insights to guide CAR T-cell product selection in older patients.
  • ||||||||||  MB-106 / Fortress
    [VIRTUAL] MBP106 - Metal Physiology at the Host-Pathogen Interface (Channel 7 ) -  May 9, 2021 - Abstract #WMF2021WMF_2044;    
    In this Symposium, we will discuss current knowledge on the regulation and mechanisms of metal homeostasis in bacterial systems, and avenues of research in the field of metallobiology of host-pathogen interactions. Upon completion of this In-depth Symposium, the participant should be able to: Describe the main host components of nutritional immunity against microbial pathogens Classify microbial systems involved in metal acquisition and metal detoxification during infection Design experiments to assess the importance of microbial metal regulatory, uptake or efflux systems in pathogenesis
  • ||||||||||  FH-TCR-T?s?? / Fred Hutchinson Cancer Center
    Trial initiation date, Metastases:  Mesothelin-Specific T-Cells (FH-TCR-T?s??) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) -  Apr 29, 2021   
    P1,  N=15, Not yet recruiting, 
    Upon completion of this In-depth Symposium, the participant should be able to: Describe the main host components of nutritional immunity against microbial pathogens Classify microbial systems involved in metal acquisition and metal detoxification during infection Design experiments to assess the importance of microbial metal regulatory, uptake or efflux systems in pathogenesis Initiation date: May 2021 --> Aug 2021
  • ||||||||||  JCAR 023 / BMS, Fred Hutchinson Cancer Center
    Enrollment change, Trial completion date, Trial primary completion date:  Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 (clinicaltrials.gov) -  Apr 27, 2021   
    P1,  N=65, Recruiting, 
    Our findings provide key insights to guide patient and CAR T-cell product selection. N=40 --> 65 | Trial completion date: Nov 2037 --> Nov 2038 | Trial primary completion date: Nov 2022 --> Nov 2023
  • ||||||||||  211At-OKT10-B10 / Fred Hutchinson Cancer Center
    New P1 trial, Combination therapy:   (clinicaltrials.gov) -  Oct 7, 2020   
    P1,  N=30, Not yet recruiting,